Home › Research › Treatments
Precision Neurology in Alzheimer's Disease: Genomics to Drug Optimization for Effective Therapeutic Intervention
Chakraborty W, Roy KK.. Molecular neurobiology, 2026-11-12
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) exhibits high clinical and biological heterogeneity, which complicates the development of one-size-fits-all therapeutic strategies. Standard trial designs can mask subgroup-specific effects, highlighting the need to move towards precision neurology entailing multisystem genomics, biomarkers, and artificial intelligence (AI) integrative signals. The aim of the study is to critically synthesize and evaluate emerging strategies for drug optimization and individual therapeutic algorithms informed by genomic architecture, pharmacogenomics (PGx), and polygenic risk scores (PRS) with the opinion to resolve the controversy and unanswered question. Amplify the convergence into amyloid processing, lipid metabolism, and innate immunity seen from monogenic mutations and over 80 GWAS risk loci. Genotyping of CYP2D6 and CYP2C19 variants permits pharmacogenomic stratifications for the optimization of cholinesterase inhibitor and psychotropic dosing, thereby reducing adverse events. Variants of the alleles APOE ε4 and immune-related factors (e.g., FCGR3A) are significant in predicting the effects of ARIA associated with amyloid on anti-amyloid immunotherapy outcomes. PRS and deep phenotyping (including digital and fluid-based biomarkers) allow for the identification of unique biological endotypes (e.g., tau-dominant vs. vascular-inflammatory) that improve clinical trial enrichment and prognostication. This framework delineates molecular endotypes and translates CYP2D6 or APOE stratification into drug dosing and ARIA risk predictions. These biomarker-driven strategies shift AD management from a passive, reactive therapeutic scheme to an active, personalized one. Utilization of high-dimensional data streams via AI-driven learning health systems converts AD management from a reactive, symptom-based model to that which is proactive and hallmark biomarker-driven precision.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chakraborty, W., & Roy, K. K. (2026). Precision Neurology in Alzheimer's Disease: Genomics to Drug Optimization for Effective Therapeutic Intervention. Molecular neurobiology. https://doi.org/10.1007/s12035-026-06313-w
Vancouver
Chakraborty W, Roy KK. Precision Neurology in Alzheimer's Disease: Genomics to Drug Optimization for Effective Therapeutic Intervention. Molecular neurobiology. 2026. doi:10.1007/s12035-026-06313-w. PMID: 43018845.
BibTeX
@article{chakraborty2026-43018845,
author = {Chakraborty, W. and Roy, K. K.},
title = {{Precision Neurology in Alzheimer's Disease: Genomics to Drug Optimization for Effective Therapeutic Intervention}},
journal = {Molecular neurobiology},
year = {2026},
doi = {10.1007/s12035-026-06313-w},
pmid = {43018845},
url = {https://doi.org/10.1007/s12035-026-06313-w}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Variants of the alleles APOE ε4 and immune-related factors (e.g., FCGR3A) are significant in predicting the effects of ARIA associated with amyloid on anti-amyloid immunotherapy outcomes.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 25 of the 58 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurobiology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 43018845) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 25 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 25 of the 58 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “neurology”
3 studies in the library carry the topic tag “neurology”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.